Resveratrol, a nontoxic natural product, exhibits multifaceted biological effects including antimutagenic and anticancer properties. We examined the effect of resveratrol on the expression and activation of Akt/protein kinase B and its impact on melanoma cell migration and invasiveness. We also explored the use of resveratrol as an antimalignant treatment option against skin melanoma in mouse models of the disease. Akt expression and activity were determined by a combination of real-time PCR and western blot analysis. Cell lines stably expressing Akt or a dominant negative variant were used to further establish the role of Akt during the response to resveratrol. Wound healing and transwell assays were used as in-vitro correlates of melanoma cell migration and invasiveness. The efficacy of resveratrol in the treatment of melanoma was assessed in two syngeneic mouse models. Resveratrol downregulated and inactivated Akt in B16F10 and B16BL6 melanoma cells. Resveratrol also inhibited the migratory and invasive properties of these highly malignant cells. The reduction of cell migration and invasion, however, was reversed in cell lines overexpressing Akt or after cotreatment with pharmacological inhibitors that blocked Akt degradation. Dominant-negative Akt cells were more sensitive to resveratrol and had diminished migratory properties. Oral treatment with resveratrol reduced primary tumor volume, Akt expression, and the propensity for metastasis in syngeneic mouse models of melanoma. These results suggest that resveratrol can reduce the malignant properties of highly invasive melanoma cells by inactivating Akt. The nontoxic targeting of Akt by resveratrol makes it an attractive treatment option for melanoma.
Introduction
The incidence of advanced cutaneous melanoma has risen rapidly in the last decades and is now responsible for the greatest number of skin cancer-related deaths [1, 2] . Although it comprises only 1% of skin cancers, malignant melanoma accounts for over 60% of skin cancer deaths [3] . Once metastasized to remote sites, it is characteristically unresponsive to treatment. At present, prevention and early detection are the most effective measures against melanoma-related mortality.
Resveratrol, a natural plant product with considerable health benefits [4] , may be an effective nontoxic chemopreventive agent. It is antiproliferative and proapoptotic for a variety of human cancer cell lines [5] . Topical administration of resveratrol already has been shown to inhibit carcinogenesis in a mouse model of melanoma [6] .
Conversion of early benign skin lesions to metastatic cutaneous melanoma occurs in stages [7] . Akt/protein kinase B, a serine/threonine kinase, is thought to play a significant role in this conversion [8] . The importance of Akt as a potential therapeutic target is further justified from studies that correlate elevated expression of Akt with the degree of malignancy in metastatic tumors arising from cutaneous melanoma [9] .
Cell migration and extracellular matrix invasion are two of the hallmarks of malignancy [10, 11] . We studied the ability of resveratrol to affect these phenotypes in vitro with highly malignant murine melanoma cell line variants B16F10, selected for its metastatic ability, and the more invasive variant B16BL6 [12] [13] [14] . Using subcutaneous and tail vein injection of B16BL6 and B16F10, respectively, we further tested whether resveratrol treatment could affect tumor growth and reduce formation of lung metastasis in syngeneic mouse models of melanoma.
We show that resveratrol deactivates and attenuates Akt. It effectively reduces the migration and invasiveness of melanoma cells in vitro and reduces tumor growth and metastasis in vivo. These properties may make this readily available bioactive food component an attractive preventive or treatment option for cutaneous melanoma.
Materials and methods
Cell culture B16BL6 and B16F10 cell lines were procured respectively from Dr I.J. Fidler (Department of Cancer Biology, MD Anderson Cancer Center, Houston, Texas) and Dr Paul M. Sondel (Departments of Pediatrics and Human Oncology, University of Wisconsin, Madison). B16BL6 cells were maintained in Eagle's minimum essential medium with 10% fetal bovine serum, 2 mm L-glutamine, 1 mmol/l sodium pyruvate, 1% nonessential amino acids, and antibiotics (10 000 units/ml penicillin, 10 mg/ml streptomycin sulfate, and 25 mg/ml amphotericin B solution, Sigma Aldrich, St Louis, Missouri, USA). B16F10 cells were maintained in RPMI media supplemented with glutamine, 10% fetal bovine serum, and antibiotics. The cells were maintained at 371C with 5% CO 2 .
Preclinical studies
Female C57 BL/6 mice, 5-6 weeks of age (Harlan Sprague-Dawley, Indianapolis, Indiana, USA), were used for the in-vivo studies. Mice were housed under pathogen-free conditions and fed standard chow and water ad libitum. Animal experiments followed guidelines of the University of Wisconsin-Madison Animal Care and Use Committee.
Primary tumor growth B16BL6 mouse melanoma cells (1 Â 10 3 ) suspended in 500 ml of 1 : 1 medium and Matrigel (Thermo-Fisher Scientific Inc., Waltham, Massachusetts, USA) were implanted subcutaneously in the dorsal flanks of C57BL/ 6 mice (n = 21). On day 4, when the tumors were palpable, mice were randomized into two treatment regimens. Group 1 (n = 10) and group 2 (n = 11) were treated with vehicle (Neobee oil) or 1 mg resveratrol suspended in Neobee oil, respectively. Solutions were administered by oral gavage daily for 17 days. Tumor volumes were measured twice a week in three dimensions by the means of calipers and the volume was approximated by multiplying the three values. At the end of treatment, animals were killed, a final measurement was made after the tumors were taken out of the animals, and tissues were processed for histology as described elsewhere [15] .
Metastasis study
B16F10 mouse melanoma cells (1 Â 10 5 ) suspended in 100 ml medium were injected into the tail vein (day 1) of C57BL/6 mice (n = 32). Mice were then randomized into two groups. The control group (n = 16) received 100 ml Neobee oil whereas the treated group (n = 16) received 1 mg of resveratrol suspended in 100 ml Neobee oil by intraperitoneal injection daily for 21 days starting on day 1. Mice were killed on day 21 and their lungs were harvested for histological processing as previously described [15] .
Wound healing assay
Plates containing confluent cultures of B16F10 cell line grown in serum-containing medium were scratched with a sterile 1 ml pipette tip. The medium was replaced with serum-free RPMI medium with resveratrol or dimethyl sulfoxide (DMSO) and returned to 371C for designated times. The cells were fixed (4% buffered paraformaldehyde), stained (0.5% crystal violet in 20% methanol), and their images were captured (RS Image Software, Tucson, Arizona, USA). Distances between the gaps formed by the scratch were measured with ImageJ software (NIH Bethesda, Maryland, USA). Percentages were calculated relative to the gap size immediately after scratching.
Migration and invasion assays
For migration assays, transwell inserts (Costar 3422, Corning Transwell polycarbonate membrane from Sigma Aldrich) were coated on the lower surface with a 5 mg/ml solution of fibronectin (Sigma) overnight at 41C. In a separate series of experiments to measure invasiveness, the upper surface of the inserts were coated with 200 mg/ml of Matrigel at room temperature followed by 5 mg/ml of fibronectin at 41C on the lower surface. Actively growing B16F10 cells were trypsinized, washed, and resuspended at 1 Â 10 6 cells/ml in serum-free RPMI medium with either DMSO or resveratrol. 1 Â 10 5 cells in 0.1 ml were carefully placed in the upper chamber. The upper and lower chambers contained the same media as the cell suspensions. After incubation for 3-4 h, cells from the upper surface were wiped clear and cells on the lower surface were fixed with 4% buffered paraformaldehyde solution. Membranes stained with hematoxylin and eosin were then transferred to slides, cover slipped, photographed, and cells were counted manually.
Western blot analysis
The cells were treated in serum-free medium with DMSO or resveratrol for designated periods before their collection by scraping, washed with cold PBS, and lysed in ice cold 1 Â radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors. Equal amounts of protein were loaded onto 15% polyacrylamide gels, transferred to polyvinylidene fluoride membrane and stained with antibodies. Mouse antipan-Akt, rabbit antiphospho (S473) Akt, and mouse antiglyceraldehyde 3-phosphate dehydrogenase antibodies were obtained from R&D systems (R&D Systems Inc., Minneapolis, Minnesota, USA). Rabbit antiphospho (T308) Akt antibody was purchased from Cell Signaling Technology Inc. (Boston, Massachusetts, USA). Antibody binding was detected using the ECL kit from Amersham GE health Care (Piscataway, New Jersey, USA) as described previously [15] . In experiments with Boc-D-Fmk, cells were coincubated with 50 mmol/l Boc-D-Fmk and resveratrol before harvest.
Generation of stable Akt cell lines
The plasmid CMV3-EE-WT-AKT-1 and the control empty vector pCMV3-EE were gifts from Anderson et al. [16] (Babraham Institute, Babraham Research Campus, Cambridge, UK). B16F10 cells were permeabilized with an Amaxa II nucleo-porator (Lonza, Basel, Switzerland) using cell line specific kit-V following the manufacturer's protocol. After 36 h, mixed populations of transfected cells were generated by pooling G418 resistant cells. The dominant-negative Akt plasmid pDSRed2 C1-Akt (PH 1-108) and the corresponding empty vector were kindly provided by Subramanyam et al. [17] (Takahashi, National Institute for Physiological Sciences, Japan). Stable transfectants were generated as described above.
Results

Resveratrol reduces the migratory properties of murine melanoma cells
The ability of cancer cells to migrate is an essential event in the progression toward malignancy. Scratch assays measure the migration of cells at the leading edge of a wound and act as an in vitro correlate to cell migration in vivo.
The data in Fig. 1 show that resveratrol inhibits the migratory property of highly invasive B16F10 melanoma cell line. Wound closure in the presence of DMSO begins within 6-8 h ( Fig. 1a ) and is complete by 17 h (Fig. 1c ). However, treatment with resveratrol inhibited cell migration (Figs 1b and d ). There was no significant change in the B16F10 cell viability during this period; 100 and 81% of the cells were viable 4 h and 24 h post-treatment, respectively.
Resveratrol inhibits the invasive properties of murine melanoma cells
By virtue of their ability to adhere to fibronectin matrices elaborated by other cells, malignant cells have enhanced invasive potential [18] . In a transwell migration assay, fibronectin serves as the chemoattractant and as an adhesive substrate for the cells. Using a filter (8 mm pore size) coated on the lower surface with fibronection and resveratrol in the medium, we showed that the number of cells that migrated through the membrane decreased to approximately 40 and 5% in the presence of 50 and 100 mmol/l of resveratrol, respectively, compared with DMSO controls (Fig. 2a ).
Invasion then requires the migration of cells through a barrier, such as basement membrane or extracellular matrix. In a similar transwell invasion assay in which the upper side of the membrane was coated with Matrigel, a solubilized basement membrane matrix, and the lower surface with fibronectin, incubation with resveratrol for 3-4 h reduced the number of cells migrating through the matrix to 4% compared with the DMSO control ( Fig. 2b ). These data suggest that resveratrol affects at least one intrinsic property of these melanoma cells, namely their ability to migrate, before any changes in viability.
Resveratrol acts like an inhibitor of Akt
Akt is a major determinant of cell migration and invasion associated with tumor aggressiveness [19] . Increased Akt activity has been reported in breast, ovarian, and prostate cancers [20] . Recently, a phase II clinical trial was conducted with perifosine, a drug that decreases cancer cell growth through decreased Akt phosphorylation in hormone-sensitive patients with prostate cancer [14] . To gain insight into the mechanisms of inhibition of melanoma cell migration and invasion, we examined the status of Akt in response to resveratrol treatment. We showed that resveratrol inactivated and attenuated Akt (Fig. 3) . B16F10 cells were treated with resveratrol for different periods and their lysates were then subjected to western blot analysis using antibodies specific for Akt and phospho-Akt (Fig. 3a) . Treatment with resveratrol caused a decrease in both phospho (S473)-Akt and phospho (T308)-Akt within 1.5 h of resveratrol addition. Thereafter, a decline in the total amount of Akt was also observed. A parallel study was conducted with Ly294002, a known Akt inhibitor (Fig. 3b) . A similar deactivation and attenuation of Akt was noted for both resveratrol and Ly294002. These data show the potential of using resveratrol as a nontoxic Akt inhibitor similar to Ly294002, a drug being considered for the treatment of melanoma [21] . Similar observations were made with B16BL6 cell line (data not shown).
Akt has three isoforms sharing a high degree of homology. All three Akt transcripts were detected in B16F10 cells.
To discern if any one of the three isoforms underwent resveratrol-mediated changes relative to the housekeeping gene Polr2A at the transcriptional level, RNA was obtained from cells treated with resveratrol. Real-time PCR analysis of the corresponding cDNAs with isoformspecific primers was performed and compared with DMSO-treated cells. No significant differences in the transcripts were observed after 4 h of resveratrol treatment. Therefore, the decline in the amount of Akt induced by resveratrol likely reflects the effect of resveratrol on protein degradation.
Boc-D-Fmk partially rescues the effects of resveratrol
The mechanism of caspase-mediated Akt cleavage is well described [22] . The pharmacological agent Boc-D-Fmk, a pan caspase inhibitor, has been used to block Akt degradation [23] . We, therefore, tested whether Boc-D-Fmk would block Akt degradation and then interfere with resveratrol-mediated inhibition of cell migration. Cotreatment of Boc-D-Fmk with resveratrol blocked Akt degradation by 50% compared with cells treated with resveratrol alone (Fig. 4a ).
Following the same treatment paradigm, Boc-D-Fmk blocked the resveratrol-mediated inhibition of melanoma cell migration (Fig. 4b ). Although only 12% of cells migrated through the membrane in the presence of resveratrol, coincubation with Boc-D-Fmk increased that value to 61%. These initial findings prompted us to investigate further the role of Akt in melanoma cell migration.
Stably transfected dominant-negative Akt cells are less invasive
Following the observations noted above, we tested whether the invasive property would be reduced in melanoma cells stably transfected with a dominant-negative Akt. To this end, melanoma cell lines were established either with a dominant-negative Akt (PH 1-108) or the corresponding empty vector control (pDS Red2-C1). The cells were then tested in transwell migration assays as previously described. As shown in Fig. 5a, 25 and 50 mmol/l of resveratrol reduced the average number of migratory cells to 86 and 52%, respectively, in cells containing an empty vector compared with the same cells treated with DMSO. As seen in the same figure, expression of dominant-negative Akt alone reduced cell migration to levels comparable with those obtained with 50 mmol/l of resveratrol. Addition of resveratrol to these cells further suppressed melanoma cell migration to final values of 37 and 24% compared with controls. This compares with the inhibitory effect of resveratrol only achievable at much higher concentrations of the compound.
These results show that inhibition of Akt, either with resveratrol or through the expression of a dominantnegative species, reduces the migratory behavior of metastatic B16F10 melanoma cells.
In contrast, the inhibition of cell migration by resveratrol was attenuated by overexpression of wild-type Akt (Fig. 5b ). In the presence of 100 mmol/l of resveratrol, approximately 55% of overexpressing Akt stable cells migrated through the Matrigel in a transwell assay compared with only 5% of cells containing the empty vector. The overexpression of wild-type Akt, therefore, partially mitigates the effect of resveratrol.
Similarly, the overexpression of Akt, made the cells less sensitive to resveratrol in a scratch assay. At 8 h postincubation, the gaps between the cells containing the empty vector with DMSO and resveratrol were 23 and 61% open respectively, whereas in the cells in which Akt is overexpressed, the wounds were completely closed in the DMSO condition and only 10% open in the presence of resveratrol.
Resveratrol treatment significantly reduces tumor growth in vivo
As migration is an essential step in the progression toward malignancy, first we determined whether resveratrol could reduce tumor growth in a syngeneic mouse model. B16BL6 cell line was selected for its highly invasive properties [12] . The cells were implanted subcutaneously, and daily treatment by oral gavage either with resveratrol or vehicle alone started 4 days later when tumors were smaller than 50 mm 3 . A reduction in tumor volume was then observed between the two groups (Fig. 6a ). Significant differences were detected after the first week of treatment, culminating at 3 weeks in a 60% inhibition of tumor growth (P = 0.001). Thus, our results showed that, similar to in-vitro findings, resveratrol interferes with the growth of tumors in vivo. During the treatment, there were no signs of toxicity; mice continued to gain weight, behaved normally, and there were no signs of damage to vital organs on necropsy.
Fresh tumor tissues also were obtained from treated and untreated mice and processed for western blot analysis to assess the levels of Akt. As shown in Fig. 6b , resveratrol treatment reduced the amount of Akt, thus paralleling our in-vitro findings.
Resveratrol treatment reduces the propensity for lung metastasis
In addition to primary tumor inhibition, resveratrol interfered with the metastasis of melanoma cells. Mice were treated daily either with vehicle or resveratrol beginning on the same day as the inoculation of cells through the tail vein. After 21 days, lungs were removed from killed mice, fixed in formalin, sectioned, and stained with hematoxylin and eosin. The area of the lung occupied by tumor in each section was assessed by two independent observers. Representative examples of treated and untreated tissue specimens are presented in Figs 6c and d, respectively. Areas of tumor (blue stain) are marked in the figures. Resveratrol-treated average tumor sizes were smaller than that of the control group with a marginal significance of 10%, (P = 0.05, SE of mean difference 8.68). Thus, there is a general trend of reduced metastasis in resveratrol-treated mice, however, a much larger number of animals would be required to determine more accurately the change in percentage.
Discussion
Despite intensive research, cutaneous melanoma is still a major cause of skin cancer-related deaths worldwide. The need to develop an effective treatment option for melanoma is significant.
Akt/protein kinase B is positioned at the crossroads of multiple oncogenic and tumor suppresser signaling networks. It promotes epithelial to mesenchymal transition and thus plays a pivotal role in enhancing the metastatic potential of cells [24, 25] . The inhibition of Akt activity therefore may provide an effective strategy for the development of an anticancer drug. However, toxicity and pharmacologic variables associated with potent Akt inhibitors has been a major obstacle when considering the use of such candidate drugs for the treatment of cutaneous melanoma [21, 26] . In contrast, we and other researchers [15, [27] [28] [29] have shown that resveratrol, a natural plant product, can effect tumor cell growth in vitro and in preclinical studies of cancer in a nontoxic manner through attenuation of antiapoptotic proteins, the activation of caspases and the loss of mitochondrial function specifically in tumor cells; that Akt is an additional target of resveratrol has been shown in this study.
We show that resveratrol, a nontoxic drug similar in activity to Ly294002, inactivates Akt and decreases the migratory and hence the invasive properties of the highly malignant melanoma cell line B16F10 in vitro. We suggest that the deactivation and attenuation of Akt underlie the resveratrol-mediated decrease of melanoma cell migration and invasiveness. This contention is supported by the partial rescue of the resveratrol-mediated effects using the pharmacological inhibitor Boc-D-Fmk. The finding that the overexpression of Akt blocks the effect of resveratrol on melanoma cell migration and invasiveness provides further support. Ultimately, the combined effects of resveratrol are shown in these studies to inhibit tumor growth and reduce metastasis in mouse models of melanoma. Although the bioavailability of resveratrol in serum may be low, and there is no evidence for its accumulation in tumors after oral administration or intraperitoneal injection, its relatively low level is still sufficient to cause significant inhibition of tumor growth in animal models of melanoma and other types of cancer without signs of significant cytotoxicity [30] . Whether resveratrol can be effective in the treatment of melanoma now needs to be ascertained in clinical trials. 1600  1400  1200  1000  800  600  400  200  0  4  7  1 1 Days 14 18 20 Resveratrol treatment reduces tumor burden and metastasis in syngeneic mouse models of melanoma. (a) B16BL6 cells were inoculated subcutaneously at day zero. Treatment with 50 mg/kg of resveratrol in Neobee oil or vehicle alone by daily oral gavage began on day 4. Tumor measurements are described in Materials and methods. (b) The western blot analysis of Akt levels in tumor specimens obtained from the mice described in (a) treated with either resveratrol or vehicle. In a separate experiment, mice were inoculated with cells through the tail vein and treated intraperitoneally either with resveratrol or with vehicle alone as described in Materials and methods. Histological sections from the lungs of resveratrol-treated (c) and untreated (d) mice were stained with hematoxylin and eosin, and tumors were demarcated using ImageJ software and their areas calculated. GADPH, glyceraldehyde 3-phosphate dehydrogenase. M, molecular weight.
